Table 1.
Baseline demographic and clinical characteristics
| Variable | Value
|
||
|---|---|---|---|
| Placebo (n=51) |
Fasinumab
|
||
| 0.1 mg/kg (n=53) |
0.3 mg/kg (n=53) |
||
| Age, years, mean ± SD | 47.3±11.9 | 45.6±12.9 | 42.6±11.6 |
| Sex, n (%) | |||
| Male | 23 (45.1) | 25 (47.2) | 26 (49.1) |
| Female | 28 (54.9) | 28 (52.8) | 27 (50.9) |
| Weight, kg, mean ± SD | 90.8±14.6 | 83.3±15.8 | 84.5±18.6 |
| Body mass index, kg/m2, mean ± SD | 31.5±5.2 | 28.3±4.3 | 29.4±5.6 |
| Hispanic or Latino ethnicity, n (%) | 7 (13.7) | 12 (22.6) | 9 (17.0) |
| Race, n (%) | |||
| White | 37 (72.5) | 40 (75.5) | 39 (73.6) |
| African American | 11 (21.6) | 10 (18.9) | 12 (20.8) |
| Asian | 0 | 1 (1.9) | 1 (1.9) |
| Other | 3 (5.9) | 2 (3.7) | 2 (3.7) |
| Duration of sciatic pain, n (%) | |||
| 2–8 weeks | 32 (62.7) | 37 (69.8) | 38 (71.7) |
| 8–16 weeks | 19 (37.3) | 16 (30.2) | 15 (28.3) |
| Average leg pain, NRS, mean ± SD | 6.2±1.5 | 6.0±1.2 | 6.1±1.4 |
| Worst leg pain, NRS, mean ± SD | 7.7±1.5 | 7.7±1.2 | 7.8±1.4 |
| Average back pain, NRS, mean ± SD | 6.2±1.9 | 6.0±1.6 | 6.1±1.8 |
| Worst back pain, NRS, mean ± SD | 7.4±2.0 | 7.8±1.5 | 7.7±2.0 |
| ODI, mean ± SD | 0.4±0.1 | 0.4±0.1 | 0.4±0.2 |
Abbreviations: NRS, numeric rating scale; ODI, Oswestry Disability Index; SD, standard deviation.